Related Experiment Videos
Emerging treatments for rheumatoid arthritis
1Clinical Research Unit, Denver Arthritis Clinic, Colorado 80220, USA.
The American Journal of Medicine
|January 27, 1997
Summary
Rheumatoid arthritis is now recognized as potentially life-threatening. Innovative immunobiologic therapies show promise in preventing disease progression, targeting inflammation beyond traditional treatments.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) was historically viewed as a non-life-threatening condition.
- Recent evidence indicates severe RA can decrease lifespan.
- Current RA treatments offer moderate symptom relief but limited impact on disease course.
Purpose of the Study:
- To review current and emerging pharmacologic therapies for rheumatoid arthritis.
- To explore innovative strategies targeting immunobiology for disease prevention.
- To assess the efficacy of novel agents in managing RA.
Main Methods:
- Review of existing literature on rheumatoid arthritis pharmacotherapies.
- Analysis of novel agents targeting cellular inflammatory mechanisms.
- Evaluation of clinical trial data for emerging RA treatments.
Main Results:
- Traditional RA therapies (NSAIDs, DMARDs, methotrexate, corticosteroids) provide moderate relief.
- Some new agents (5-lipoxygenase inhibitors, zileuton) may suit milder RA.
- Promising but inconsistently effective agents include oral type II collagen, minocycline, IL-1ra, and anti-CD4 antibodies.
- Tumor necrosis factor-alpha inhibitors, cyclosporine, mycophenolate mofetil, and tenidap are among the most promising.
Conclusions:
- Standard RA treatments have limited impact on disease progression.
- Innovative immunobiologic strategies are crucial for preventing RA progression.
- Further research is needed for many novel agents, but TNF-alpha inhibitors and others show significant potential.